Xian Deng
Stock Analyst at UBS
(4.53)
# 1,004
Out of 4,574 analysts
167
Total ratings
64.4%
Success rate
17.1%
Average return
Main Sectors:
Stocks Rated by Xian Deng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0NZT UCB SA | Maintained: Buy | €330.00 | €240.88 | +37.00% | 23 | Jun 9, 2026 | |
| EPA: IPN Ipsen S.A. | Maintained: Hold | €137.00 → €170.00 | €158.40 | +7.32% | 23 | May 19, 2026 | |
| ARGX argenx SE | Maintained: Hold | $850 | $918.22 | -7.43% | 33 | May 8, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Hold | n/a | $815.30 | - | 12 | May 8, 2026 | |
| ZLDPF Zealand Pharma A/S | Maintained: Buy | $116 → $111 | $45.01 | +146.67% | 3 | May 8, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Maintained: Hold | €30.00 | €24.50 | +22.45% | 4 | Apr 1, 2026 | |
| LON: 0MGB Genmab A/S | Rated: Buy | kr 2,750 → kr 2,600 | kr 1,877 | +38.49% | 36 | Mar 26, 2026 | |
| SWX: BIOV BioVersys AG | Initiated Coverage: Buy | CHF 48.00 | CHF 27.30 | +75.82% | 2 | Dec 11, 2025 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | CHF 720.00 → CHF 605.00 | CHF 548.00 | n/a | 12 | Feb 6, 2023 | |
| FRA: MDG1 Medigene AG | Maintained: Buy | €8.00 | €0.02 | n/a | 6 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | kr 480.00 → kr 450.00 | kr 500.90 | n/a | 7 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | kr 255.00 | kr 198.44 | n/a | 2 | Feb 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €31.00 | €18.74 | n/a | 4 | Nov 1, 2019 |
UCB SA
Jun 9, 2026
Maintained: Buy
Price Target: €330.00
Current: €240.88
Upside: +37.00%
Ipsen S.A.
May 19, 2026
Maintained: Hold
Price Target: €137.00 → €170.00
Current: €158.40
Upside: +7.32%
argenx SE
May 8, 2026
Maintained: Hold
Price Target: $850
Current: $918.22
Upside: -7.43%
argenx SE
May 8, 2026
Maintained: Hold
Price Target: n/a
Current: $815.30
Upside: -
Zealand Pharma A/S
May 8, 2026
Maintained: Buy
Price Target: $116 → $111
Current: $45.01
Upside: +146.67%
Lakefront Biotherapeutics NV
Apr 1, 2026
Maintained: Hold
Price Target: €30.00
Current: €24.50
Upside: +22.45%
Genmab A/S
Mar 26, 2026
Rated: Buy
Price Target: kr 2,750 → kr 2,600
Current: kr 1,877
Upside: +38.49%
BioVersys AG
Dec 11, 2025
Initiated Coverage: Buy
Price Target: CHF 48.00
Current: CHF 27.30
Upside: +75.82%
Lonza Group AG
Feb 6, 2023
Maintained: Buy
Price Target: CHF 720.00 → CHF 605.00
Current: CHF 548.00
Upside: n/a
Medigene AG
Aug 4, 2022
Maintained: Buy
Price Target: €8.00
Current: €0.02
Upside: n/a
May 26, 2020
Downgraded: Hold
Price Target: kr 480.00 → kr 450.00
Current: kr 500.90
Upside: n/a
Feb 17, 2020
Maintained: Buy
Price Target: kr 255.00
Current: kr 198.44
Upside: n/a
Nov 1, 2019
Maintained: Buy
Price Target: €31.00
Current: €18.74
Upside: n/a